- Home
- ACET vs ORMP Comparison
ACET vs ORMP Comparison
Compare ACET & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- ORMP
- Stock Information
- Founded
- ACET 1947
- ORMP 2002
- Country
- ACET United States
- ORMP United States
- Employees
- ACET N/A
- ORMP N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- ORMP Biotechnology: Pharmaceutical Preparations
- Sector
- ACET Health Care
- ORMP Health Care
- Exchange
- ACET Nasdaq
- ORMP Nasdaq
- Market Cap
- ACET 70.3M
- ORMP 84.3M
- IPO Year
- ACET N/A
- ORMP N/A
- Fundamental
- Price
- ACET $0.72
- ORMP $2.20
- Analyst Decision
- ACET Buy
- ORMP Hold
- Analyst Count
- ACET 6
- ORMP 1
- Target Price
- ACET $6.00
- ORMP N/A
- AVG Volume (30 Days)
- ACET 324.2K
- ORMP 99.0K
- Earning Date
- ACET 03-06-2025
- ORMP 03-27-2025
- Dividend Yield
- ACET N/A
- ORMP N/A
- EPS Growth
- ACET N/A
- ORMP N/A
- EPS
- ACET N/A
- ORMP N/A
- Revenue
- ACET N/A
- ORMP N/A
- Revenue This Year
- ACET N/A
- ORMP N/A
- Revenue Next Year
- ACET N/A
- ORMP N/A
- P/E Ratio
- ACET N/A
- ORMP N/A
- Revenue Growth
- ACET N/A
- ORMP N/A
- 52 Week Low
- ACET $0.69
- ORMP $1.96
- 52 Week High
- ACET $2.40
- ORMP $3.09
- Technical
- Relative Strength Index (RSI)
- ACET 37.26
- ORMP 43.45
- Support Level
- ACET $0.74
- ORMP $2.06
- Resistance Level
- ACET $0.91
- ORMP $2.40
- Average True Range (ATR)
- ACET 0.06
- ORMP 0.09
- MACD
- ACET -0.00
- ORMP -0.03
- Stochastic Oscillator
- ACET 12.61
- ORMP 35.00
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.